Trump Directs USTR To Prioritize Drug IP, Market Access In Bid To Lower U.S. Prices

May 14, 2018
President Donald Trump has directed U.S. Trade Representative Robert Lighthizer to ensure that intellectual property and market access policies in trade deals contribute to lower drug prices in the United States. HHS also discussed the issue in a request for information issued Monday (May 14) seeking stakeholders' feedback on myriad drug cost-containment ideas floated by the president. “The U.S. Trade Representative will prioritize addressing unfair intellectual property and market access policies in our trade agreements, so that partners contribute their...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.